Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
Portfolio Pulse from
Genprex, Inc. has completed the Phase 1 dose escalation portion of its Acclaim-3 clinical trial for Reqorsa® Gene Therapy in combination with Tecentriq® for treating extensive stage small cell lung cancer. The Safety Review Committee has approved the trial to advance to Phase 2.
December 16, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genprex has received approval to advance to Phase 2 of its Acclaim-3 trial for Reqorsa® Gene Therapy in combination with Tecentriq® after favorable Phase 1 results, indicating a positive safety profile.
The completion of Phase 1 with a favorable safety profile and the approval to proceed to Phase 2 is a positive development for Genprex, potentially increasing investor confidence and interest in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100